Dexcom annual shares outstanding
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Dexcom Shares Outstanding History (DXCM)
Dexcom reported 384.8M shares outstanding at the end of fiscal 2025.
View full Dexcom company overviewDexcom annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 384.8M | −5.9M | −1.51% |
| 2024 | 2024-12-31 | 390.7M | 5.3M | +1.38% |
| 2023 | 2023-12-31 | 385.4M | −900,000 | −0.23% |
| 2022 | 2022-12-31 | 386.3M | −1.7M | −0.44% |
| 2021 | 2021-12-31 | 388.0M | 3.6M | +0.94% |
| 2020 | 2020-12-31 | 384.4M | 18.0M | +4.91% |
| 2019 | 2019-12-31 | 366.4M | 6.4M | +1.78% |
| 2018 | 2018-12-31 | 360.0M | 12.0M | +3.45% |
| 2017 | 2017-12-31 | 348.0M | 9.6M | +2.84% |
| 2016 | 2016-12-31 | 338.4M | 11.6M | +3.55% |
| 2015 | 2015-12-31 | 326.8M | 17.6M | +5.69% |
| 2014 | 2014-12-31 | 309.2M | 19.2M | +6.62% |
| 2013 | 2013-12-31 | 290.0M | 12.0M | +4.32% |
| 2012 | 2012-12-31 | 278.0M | 8.0M | +2.96% |
| 2011 | 2011-12-31 | 270.0M | 21.7M | +8.73% |
| 2010 | 2010-12-31 | 248.3M | — | — |
Dexcom quarterly shares outstanding
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 377.4M | −14.8M | −3.77% |
| Q1 2026 | 2026-03-31 | 385.9M | −6.2M | −1.58% |
| Q4 2025 | 2025-12-31 | 384.8M | −5.9M | −1.51% |
| Q3 2025 | 2025-09-30 | 390.0M | −600,000 | −0.15% |
| Q2 2025 | 2025-06-30 | 392.2M | −8.5M | −2.12% |
| Q1 2025 | 2025-03-31 | 392.1M | −4.0M | −1.01% |
| Q4 2024 | 2024-12-31 | 390.7M | 5.3M | +1.38% |
| Q3 2024 | 2024-09-30 | 390.6M | 4.2M | +1.09% |
| Q2 2024 | 2024-06-30 | 400.7M | 14.6M | +3.78% |
| Q1 2024 | 2024-03-31 | 396.1M | 8.5M | +2.19% |
| Q4 2023 | 2023-12-31 | 385.4M | −900,000 | −0.23% |
| Q3 2023 | 2023-09-30 | 386.4M | 200,000 | +0.05% |
| Q2 2023 | 2023-06-30 | 386.1M | −6.5M | −1.66% |
| Q1 2023 | 2023-03-31 | 387.6M | −4.8M | −1.22% |
| Q4 2022 | 2022-12-31 | 386.3M | −1.7M | −0.44% |
| Q3 2022 | 2022-09-30 | 386.2M | −1.4M | −0.36% |
| Q2 2022 | 2022-06-30 | 392.6M | 5.8M | +1.50% |
| Q1 2022 | 2022-03-31 | 392.4M | 5.6M | +1.45% |
| Q4 2021 | 2021-12-31 | 388.0M | 3.6M | +0.94% |
| Q3 2021 | 2021-09-30 | 387.6M | 3.6M | +0.94% |
| Q2 2021 | 2021-06-30 | 386.8M | 5.2M | +1.36% |
| Q1 2021 | 2021-03-31 | 386.8M | 17.6M | +4.77% |
| Q4 2020 | 2020-12-31 | 384.4M | 18.0M | +4.91% |
| Q3 2020 | 2020-09-30 | 384.0M | 18.0M | +4.92% |
| Q2 2020 | 2020-06-30 | 381.6M | 16.8M | +4.61% |
| Q1 2020 | 2020-03-31 | 369.2M | 5.2M | +1.43% |
| Q4 2019 | 2019-12-31 | 366.4M | 6.4M | +1.78% |
| Q3 2019 | 2019-09-30 | 366.0M | 10.8M | +3.04% |
| Q2 2019 | 2019-06-30 | 364.8M | 11.2M | +3.17% |
| Q1 2019 | 2019-03-31 | 364.0M | 11.6M | +3.29% |
| Q4 2018 | 2018-12-31 | 360.0M | 12.0M | +3.45% |
| Q3 2018 | 2018-09-30 | 355.2M | 7.6M | +2.19% |
| Q2 2018 | 2018-06-30 | 353.6M | 7.6M | +2.20% |
| Q1 2018 | 2018-03-31 | 352.4M | 7.2M | +2.09% |
| Q4 2017 | 2017-12-31 | 348.0M | 9.6M | +2.84% |
| Q3 2017 | 2017-09-30 | 347.6M | 9.6M | +2.84% |
| Q2 2017 | 2017-06-30 | 346.0M | 10.8M | +3.22% |
| Q1 2017 | 2017-03-31 | 345.2M | 11.6M | +3.48% |
| Q4 2016 | 2016-12-31 | 338.4M | 11.6M | +3.55% |
| Q3 2016 | 2016-09-30 | 338.0M | 12.8M | +3.94% |
| Q2 2016 | 2016-06-30 | 335.2M | 15.2M | +4.75% |
| Q1 2016 | 2016-03-31 | 333.6M | 16.8M | +5.30% |
| Q4 2015 | 2015-12-31 | 326.8M | 17.6M | +5.69% |
| Q3 2015 | 2015-09-30 | 325.2M | 19.6M | +6.41% |
| Q2 2015 | 2015-06-30 | 320.0M | 18.4M | +6.10% |
| Q1 2015 | 2015-03-31 | 316.8M | 17.6M | +5.88% |
| Q4 2014 | 2014-12-31 | 309.2M | 19.2M | +6.62% |
| Q3 2014 | 2014-09-30 | 305.6M | 18.8M | +6.56% |
| Q2 2014 | 2014-06-30 | 301.6M | 16.8M | +5.90% |
| Q1 2014 | 2014-03-31 | 299.2M | 16.4M | +5.80% |
| Q4 2013 | 2013-12-31 | 290.0M | 12.0M | +4.32% |
| Q3 2013 | 2013-09-30 | 286.8M | 9.8M | +3.54% |
| Q2 2013 | 2013-06-30 | 284.8M | 9.2M | +3.33% |
| Q1 2013 | 2013-03-31 | 282.8M | 8.6M | +3.14% |
| Q4 2012 | 2012-12-31 | 278.0M | 8.0M | +2.96% |
| Q3 2012 | 2012-09-30 | 277.0M | 7.0M | +2.59% |
| Q2 2012 | 2012-06-30 | 275.6M | 6.3M | +2.34% |
| Q1 2012 | 2012-03-31 | 274.2M | — | — |
| Q4 2011 | 2011-12-31 | 270.0M | 21.7M | +8.73% |
| Q3 2011 | 2011-09-30 | 270.0M | — | — |
| Q2 2011 | 2011-06-30 | 269.3M | — | — |
| Q4 2010 | 2010-12-31 | 248.3M | — | — |
Dexcom Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Dexcom share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Dexcom used $500.0M to repurchase common stock in fy 2025. Across the latest 5 reported fiscal years, total share repurchases were $2.50B. The latest reported quarter showed $312.8M of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | $500.0M |
| 2024 | 2024-12-31 | $750.0M |
| 2023 | 2023-12-31 | $688.7M |
| 2022 | 2022-12-31 | $557.7M |
| 2021 | 2021-12-31 | $0 |
| 2020 | 2020-12-31 | $0 |
| 2019 | 2019-12-31 | $0 |
| 2018 | 2018-12-31 | $100.0M |
| 2017 | 2017-12-31 | $0 |
| 2016 | 2016-12-31 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Dexcom shares outstanding trends
Over the last five fiscal years, Dexcom's shares outstanding moved from 384.4M to 384.8M, a change of 400,000. The latest reported quarter, Q2 2026, shows 377.4M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dexcom source filings ↗Community posts
Dexcom raises revenue and margin targets and authorizes a $1 billion buyback
Dexcom ($DXCM) lifted its 2026 sales forecast to $5.20–$5.25 billion, raising the midpoint, and increased its adjusted operating-margin target to approximately 24%. Third-quarter 2026 revenue increased 11% to $1.34 billion, with US growth o ...
